Active Biotech's Prostate Cancer Project TASQ Featured In British Journal Of Cancer

British Journal of Cancer (doi: 10.1038/sj.bjc.6605322) releases an article covering Active Biotech's (NASDAQ OMX Nordic: ACTI) prostate cancer project TASQ, where TASQ was studied as a single agent in patients with castration-resistant prostate cancer.